FATE News and Press, Fate Therapeutics Inc. From 11/12/20

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming in...

Image source: The Motley Fool. Fate Therapeutics Inc (NASDAQ: FATE) Q3 2020 Earnings Call Nov 6, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Fate Therapeutics Inc (FATE) Q3 2020 Earnings Call Transcript

Fate Therapeutics, Inc. (FATE) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Edward Dulac - Chief Financial Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne...

Fate Therapeutics (FATE): Q3 GAAP EPS of -$0.68 misses by $0.36.Revenue of $7.56M (+211.1% Y/Y) beats by $0.07M.Press Release For further details see: Fate Therapeutics EPS misses by $0.36, beats on revenue

First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab for B-cell Lymphoma FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic Leukemia First Patient Treated with FT516 in Combination with Avelumab for Advanced Solid Tum...

Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event on Friday, December 4 SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage bioph...

[[AAXN]], [[ACLS]], [[ADT]], [[AGO]], [[AIG]], [[AINV]], [[ALRM]], [[ALTR]], [[AMCR]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[ATGE]], [[ATRC]], [[AVLR]], [[AYX]], [[AZPN]], [[BFAM]], [[BGS]], [[BHF]], [[BIGC]], [[BILL]], [[BKNG]], [[BLDP]], [[BMRN]], [[BNFT]], [[CABO]], [[CARG]], [[CDAY]], [...

Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is -$0.36 (+10.0% Y/Y) and the consensus Revenue Estimate is $7.49M (+208.2% Y/Y).Over the last 1 year, FATE has beaten EPS estimates 0% of the...

SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company will host a conference call a...

Amgen Inc. (AMGN) is benefiting from high global demand for its product portfolio and generating positive topline results as evident from its recently released financial results. However, the stock has lost nearly 13% in the past month due to no updates on its COVID-19 therapy or vaccine. Fin...